BofA raised the firm’s price target on BioNTech (BNTX) to $134 from $126 and keeps a Buy rating on the shares. The company’s Q2 results saw revenue well ahead of consensus expectations, with the firm also noting that its COVID revenues provide runway for further pipeline execution, the analyst tells investors in a research note. BioNTech also remains committed to maintaining differentiation through variant-adapted boosters and combo vaccine development, BofA added.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BioNTech SE: Strategic Growth and Innovation in Oncology Amidst Strong Financial Foundation
- Cautious Hold on BioNTech SE Amid Revenue Uncertainty and Competitive Challenges
- BioNTech price target raised to $185 from $181 at Clear Street
- BioNTech SE Reports Strong Financial Results for Mid-2025
- BioNTech Reports Q2 2025 Financials and Strategic Collaborations